Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

FDA Approval Volume through three Quarters

10/17/2018

 
Last spring, I looked at the trend in the number of new drug approvals by the FDA. The FDA was coming off a year with a greatly increased number of approvals compared to the previous year. When looked at over time, it appeared this was a long term trend that built on streamlining and optimizing the drug approval process. Thus, 2017 was similar to 2015 and just a little higher than 2012 and 2014.  So, compared to 2016, 2017 looked more in line with the 2014-2015 trend in drug approvals and 2016 had a reduced number compared to previous years. 
Picture
After one quarter, it appeared that 2018 was going to look more like 2016 with fewer drug approvals. I even wrote an editorial suggesting this but cautioned that it was still early to forecast the final volume. 
Picture
The FDA has been updating guidance that it issues for the development of drugs. As an example, new guidance for five neurological conditions was released at the beginning of the year. This new guidance along with new types of clinical trial methodologies such as adaptive trials have has effectively brought more drugs into the final stages of development. The FDA approved a greater number of drugs each month from May to September in 2018. The only exception was June, when they equaled the previous highest total. Through three quarters, the FDA is now on track to exceed the number of drugs approved in 2017 with the highest number of total approvals in seven years.
Picture
There has also been an increase in the number of generic drugs approved. The FDA uses an October to September fiscal year and reported 781 drugs approved in fiscal year 2018 compared to 763 in fiscal 2017. As with branded drugs, the FDA has also been releasing guidance documents to streamline approval of generic drugsand to promote competition for single source drugs with no patent protection. The FDA’s generic approval program should increase the number of manufacturers and help stabilize drug supplies and lower prices. 
 
Subscribe to the Pharmaceutical Pipeline Tracker for only $115 per month to take a deeper dive into the investigational drug universe: https://www.prescriberight.com/subscription-offers.html
 
Search for budget busting drugs by clicking on our “Current list of drugs with PDUFA”date   button to review upcoming approval deadlines and any drugs with priority designations. Follow this link to view our case studies: https://www.prescriberight.com/case-studies.html
 
Contact us with specific requests or questions at https://www.prescriberight.com/contact.html


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.